SGLT-2-Inhibitoren – Eine Standortbestimmung in der deutschen oralen Therapielandschaft für Menschen mit Typ-2-Diabetes

 

 Buy Article Permissions and Reprints

Zusammenfassung

Wie aus zahlreichen umfangreichen Studien hervorgeht, haben SGLT-2-Inhibitoren nicht nur positive Effekte auf den Glukosestoffwechsel, sondern darüber hinaus eine ausgeprägte protektive Wirkung auf Herz und Nieren. Damit kommt dieser Wirkstoffklasse eine wichtige Rolle in der Primär- und Sekundärprävention diabetes-assoziierter Komorbiditäten zu. Leitlinien sprechen auf Basis der Evidenz für SGLT-2-Inhibitoren eine Empfehlung für deren frühen Einsatz bei Menschen mit Typ-2-Diabetes und gleichzeitigem hohen Risiko für kardiovaskuläre und/oder renale Ereignisse aus. Verordnungszahlen zeigen jedoch, dass diese Empfehlungen aktuell nicht umgesetzt werden und deutlich mehr Menschen mit Typ-2-Diabetes von einer organprotektiven Therapie profitieren könnten. Daher soll in dieser Übersichtsarbeit der Stellenwert der SGLT-2-Inhibitoren im Vergleich zu anderen oralen Therapieansätzen für die Behandlung des Typ-2-Diabetes dargestellt werden.

Abstract

As numerous extensive studies have shown, SGLT2 inhibitors not only have beneficial effects on glucose metabolism, but also have a pronounced protective effect on the heart and kidneys. This class of drugs therefore plays an important role in the primary and secondary prevention of diabetes-associated comorbidities. Based on the evidence for SGLT2 inhibitors, guidelines recommend their early use in people with type 2 diabetes being at high risk of cardiovascular and/or renal events. However, prescription data show that these recommendations are currently not implemented and that significantly more people with type 2 diabetes could benefit from organ-protective therapy. Therefore, the aim of this review is to present the value of SGLT2 inhibitors in comparison to other oral therapeutic approaches for the treatment of type 2 diabetes.

Publication History

Received: 13 August 2024

Accepted after revision: 07 October 2024

Article published online:
16 December 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

• Literatur

• 1 Deutsche Diabetes Gesellschaft (DDG). Deutscher Gesundheitsbericht Diabetes 2024 (14.11.2023). Accessed July 30, 2024 at: https://www.ddg.info/fileadmin/user_upload/Gesundheitsbericht_2024_Endversion.pdf
• 2 Tönnies T, Röckl S, Hoyer A. et al. Projected number of people with diagnosed Type 2 diabetes in Germany in 2040. Diabetic Medicine 2019; 36: 1217-1225
  CrossrefPubMedSearch in Google Scholar
• 3 Bongaerts B, Kollhorst B, Kuss O. et al. Dispensation Patterns of Glucose-Lowering Drugs in Newly Diagnosed Type 2 Diabetes: Routine Data Analysis of Insurance Claims in Germany. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2022; 130: 587-595
  Thieme ConnectPubMedSearch in Google Scholar
• 4 Wilke T, Picker N, Mueller S. et al. Real-world insulin therapy in German type 2 diabetes mellitus patients: patient characteristics, treatment patterns, and insulin dosage. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2019; 12: 1225-1237
  CrossrefPubMedSearch in Google Scholar
• 5 Barth SD, Kostev K, Krensel M. et al. Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2023; 131: 153-161
  Thieme ConnectPubMedSearch in Google Scholar
• 6 Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London, England) 2022; 400: 1788-1801
  CrossrefPubMedSearch in Google Scholar
• 7 Vaduganathan M, Docherty KF, Claggett BL. et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet (London, England) 2022; 400: 757-767
  CrossrefPubMedSearch in Google Scholar
• 8 Dal Canto E, Ceriello A, Ryden L. et al. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26: 25-32
  CrossrefPubMedSearch in Google Scholar
• 9 Ene-Iordache B, Perico N, Bikbov B. et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. Lancet Glob Health 2016; 4: e307-319
  CrossrefPubMedSearch in Google Scholar
• 10 Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabetic medicine : a journal of the British Diabetic Association 2010; 27: 136-142
  CrossrefPubMedSearch in Google Scholar
• 11 Fonseca-Correa JI, Correa-Rotter R. Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review. Front Med (Lausanne) 2021; 8: 777861
  CrossrefPubMedSearch in Google Scholar
• 12 Bakris GL, Fonseca VA, Sharma K. et al. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney international 2009; 75: 1272-1277
  CrossrefPubMedSearch in Google Scholar
• 13 Palmer BF, Clegg DJ. Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy. Clinical journal of the American Society of Nephrology : CJASN 2021; 16: 1284-1291
  CrossrefPubMedSearch in Google Scholar
• 14 Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nature reviews Cardiology 2020; 17: 761-772
  CrossrefPubMedSearch in Google Scholar
• 15 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes – Langfassung. 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014.
  Crossref
• 16 Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes – Langfassung. Version 3.0. 2023
  CrossrefSearch in Google Scholar
• 17 He G, Yang G, Huang X. et al. SGLT2 inhibitors for prevention of primary and secondary cardiovascular outcomes: A meta-analysis of randomized controlled trials. Heart Lung 2023; 59: 109-116
  CrossrefPubMedSearch in Google Scholar
• 18 Zelniker TA, Wiviott SD, Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet (London, England) 2019; 393: 31-39
  CrossrefPubMedSearch in Google Scholar
• 19 Mosenzon O, Raz I, Wiviott SD. et al. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Diabetes Care 2022; 45: 2350-2359
  CrossrefPubMedSearch in Google Scholar
• 20 Fadini GP, Longato E, Morieri ML. et al. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk. Lancet Reg Health Eur 2024; 38: 100847
  CrossrefPubMedSearch in Google Scholar
• 21 Wanner C, Inzucchi SE, Zinman B. et al. Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. Diabetes, obesity & metabolism 2020; 22: 2335-2347
  CrossrefPubMedSearch in Google Scholar
• 22 Ceriello A, Lucisano G, Prattichizzo F. et al. The legacy effect of hyperglycemia and early use of SGLT-2 inhibitors: a cohort study with newly-diagnosed people with type 2 diabetes. Lancet Reg Health Eur 2023; 31: 100666
  CrossrefPubMedSearch in Google Scholar
• 23 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England journal of medicine 2015; 373: 2117-2128
  CrossrefPubMedSearch in Google Scholar
• 24 Wiviott SD, Raz I, Bonaca MP. et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England journal of medicine 2019; 380: 347-357
  CrossrefPubMedSearch in Google Scholar
• 25 Cahn A, Raz I, Leiter LA. et al. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care 2021; 44: 1159-1167
  CrossrefPubMedSearch in Google Scholar
• 26 McMurray JJV, Wheeler DC, Stefansson BV. et al. Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease. Circulation 2021; 143: 438-448
  CrossrefPubMedSearch in Google Scholar
• 27 Feng M, Lv H, Xu X. et al. Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine 2019; 98: e16575
  CrossrefPubMedSearch in Google Scholar
• 28 McNeill AM, Davies G, Kruger E. et al. Ertugliflozin Compared to Other Anti-hyperglycemic Agents as Monotherapy and Add-on Therapy in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 2019; 10: 473-491
  CrossrefPubMedSearch in Google Scholar
• 29 Zhang F, Wang W, Hou X. Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta-analysis of data from randomized controlled trials. J Diabetes Investig 2022; 13: 478-488
  CrossrefPubMedSearch in Google Scholar
• 30 Xu X, Xu W, Zhuo Q. et al. The efficacy and safety of dapagliflozin combined with oral hypoglycemic agents in patients with type 2 diabetes: a systematic review and meta-analysis. Ann Palliat Med 2022; 11: 1028-1037
  CrossrefPubMedSearch in Google Scholar
• 31 Zhang YJ, Han SL, Sun XF. et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials. Medicine 2018; 97: e12843
  CrossrefPubMedSearch in Google Scholar
• 32 Liu L, Shi FH, Xu H. et al. Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Front Pharmacol 2021; 12: 752440
  CrossrefPubMedSearch in Google Scholar
• 33 Kudo A, Machii N, Ono T. et al. Effect of dapagliflozin on 24-hour glycemic variables in Japanese patients with type 2 diabetes mellitus receiving basal insulin supported oral therapy (DBOT): a multicenter, randomized, open-label, parallel-group study. BMJ Open Diabetes Res Care 2023; 11
  CrossrefPubMedSearch in Google Scholar
• 34 Bailey CJ, Gross JL, Hennicken D. et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med 2013; 11: 43
  CrossrefPubMedSearch in Google Scholar
• 35 Bailey CJ, Morales Villegas EC, Woo V. et al. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabetic medicine : a journal of the British Diabetic Association 2015; 32: 531-541
  CrossrefPubMedSearch in Google Scholar
• 36 Roden M, Merker L, Christiansen AV. et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovascular diabetology 2015; 14: 154
  CrossrefPubMedSearch in Google Scholar
• 37 Merker L, Haring HU, Christiansen AV. et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association 2015; 32: 1555-1567
  CrossrefPubMedSearch in Google Scholar
• 38 Gallo S, Charbonnel B, Goldman A. et al. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes, obesity & metabolism 2019; 21: 1027-1036
  CrossrefPubMedSearch in Google Scholar
• 39 Aronson R, Frias J, Goldman A. et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. Diabetes, obesity & metabolism 2018; 20: 1453-1460
  CrossrefPubMedSearch in Google Scholar
• 40 Gu S, Hu X, Shi L. et al. Choice of Glucose-Lowering Drugs as Initial Monotherapy for Type 2 Diabetes Patients with Contraindications or Intolerance to Metformin: A Systematic Review and Meta-Analysis. J Clin Med 2022; 11
  CrossrefPubMedSearch in Google Scholar
• 41 Qian D, Zhang T, Zheng P. et al. Comparison of Oral Antidiabetic Drugs as Add-On Treatments in Patients with Type 2 Diabetes Uncontrolled on Metformin: A Network Meta-Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 2018; 9: 1945-1958
  CrossrefPubMedSearch in Google Scholar
• 42 Collier A, Meney C, Hair M. et al. Cancer has overtaken cardiovascular disease as the commonest cause of death in Scottish type 2 diabetes patients: A population-based study (The Ayrshire Diabetes Follow-up Cohort study). J Diabetes Investig 2020; 11: 55-61
  CrossrefPubMedSearch in Google Scholar
• 43 Pearson-Stuttard J, Bennett J, Cheng YJ. et al. Trends in predominant causes of death in individuals with and without diabetes in England from 2001 to 2018: an epidemiological analysis of linked primary care records. The lancet Diabetes & endocrinology 2021; 9: 165-173
  CrossrefPubMedSearch in Google Scholar
• 44 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England journal of medicine 2017; 377: 644-657
  CrossrefPubMedSearch in Google Scholar
• 45 Perkovic V, Jardine MJ, Neal B. et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England journal of medicine 2019; 380: 2295-2306
  CrossrefPubMedSearch in Google Scholar
• 46 McMurray JJV, Solomon SD, Inzucchi SE. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England journal of medicine 2019; 381: 1995-2008
  CrossrefPubMedSearch in Google Scholar
• 47 Packer M, Anker SD, Butler J. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. The New England journal of medicine 2020; 383: 1413-1424
  CrossrefPubMedSearch in Google Scholar
• 48 Heerspink HJL, Stefansson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine 2020; 383: 1436-1446
  CrossrefPubMedSearch in Google Scholar
• 49 Bhatt DL, Szarek M, Pitt B. et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. The New England journal of medicine 2021; 384: 129-139
  CrossrefPubMedSearch in Google Scholar
• 50 Cannon CP, Pratley R, Dagogo-Jack S. et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. The New England journal of medicine 2020; 383: 1425-1435
  CrossrefPubMedSearch in Google Scholar
• 51 Bhatt DL, Szarek M, Steg PG. et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England journal of medicine 2020; 384: 117-128
  CrossrefPubMedSearch in Google Scholar
• 52 Anker SD, Butler J, Filippatos G. et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England journal of medicine 2021;
  CrossrefPubMedSearch in Google Scholar
• 53 Solomon SD, de Boer RA, DeMets D. et al. Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. European journal of heart failure 2021; 23: 1217-1225
  CrossrefPubMedSearch in Google Scholar
• 54 Herrington WG, Staplin N. The EMPA-KIDNEY Collaborative Group. et al. Empagliflozin in Patients with Chronic Kidney Disease. The New England journal of medicine 2023; 388: 117-127
  CrossrefPubMedSearch in Google Scholar
• 55 James S, Erlinge D, Storey RF. et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid 2024; 3: EVIDoa2300286
  CrossrefPubMedSearch in Google Scholar
• 56 Butler J, Jones WS, Udell JA. et al. Empagliflozin after Acute Myocardial Infarction. The New England journal of medicine 2024; 390: 1455-1466
  CrossrefPubMedSearch in Google Scholar
• 57 Schechter M, Wiviott SD, Raz I. et al. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. The lancet Diabetes & endocrinology 2023; 11: 233-241
  CrossrefPubMedSearch in Google Scholar
• 58 Jhund PS, Kondo T, Butt JH. et al. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER. Nature medicine 2022; 28: 1956-1964
  CrossrefPubMedSearch in Google Scholar
• 59 Butler J, Packer M, Filippatos G. et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European heart journal 2022; 43: 416-426
  CrossrefPubMedSearch in Google Scholar
• 60 Cosentino F, Cannon CP, Cherney DZI. et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation 2020; 142: 2205-2215
  CrossrefPubMedSearch in Google Scholar
• 61 Khunti K, Kosiborod M, Kim DJ. et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data. Cardiovascular diabetology 2021; 20: 159
  CrossrefPubMedSearch in Google Scholar
• 62 Heerspink HJL, Karasik A, Thuresson M. et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. The lancet Diabetes & endocrinology 2020; 8: 27-35
  CrossrefPubMedSearch in Google Scholar
• 63 Schernthaner G, Brand K, Bailey CJ. Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure. Metabolism: clinical and experimental 2022; 130: 155160
  CrossrefPubMedSearch in Google Scholar
• 64 Bergmark BA, Bhatt DL, McGuire DK. et al. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation 2019; 140: 1004-1014
  CrossrefPubMedSearch in Google Scholar
• 65 Holman RR, Paul SK, Bethel MA. et al. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England journal of medicine 2008; 359: 1577-1589
  CrossrefPubMedSearch in Google Scholar
• 66 Vaccaro O, Masulli M, Nicolucci A. et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. The lancet Diabetes & endocrinology 2017; 5: 887-897
  CrossrefPubMedSearch in Google Scholar
• 67 Rosenstock J, Kahn SE, Johansen OE. et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. Jama 2019; 322: 1155-1166
  CrossrefPubMedSearch in Google Scholar
• 68 Maiorino MI, Longo M, Scappaticcio L. et al. Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular diabetology 2021; 20: 210
  CrossrefPubMedSearch in Google Scholar
• 69 Giugliano D, Longo M, Signoriello S. et al. The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs. Cardiovascular diabetology 2022; 21: 42
  CrossrefPubMedSearch in Google Scholar
• 70 Qiu M, Ding LL, Zhang M. et al. Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors. Diabetes & vascular disease research 2021; 18: 14791641211011016
  CrossrefPubMedSearch in Google Scholar
• 71 Kalra S, Baruah MP, Sahay R. Medication counselling with sodium glucose transporter 2 inhibitor therapy. Indian J Endocrinol Metab 2014; 18: 597-599
  CrossrefPubMedSearch in Google Scholar
• 72 Williams SM, Ahmed SH. 1224-P: Improving Compliance with SGLT2 Inhibitors by Reducing the Risk of Genital Mycotic Infections: The Outcomes of Personal Hygiene Advice. Diabetes 2019; 68
  CrossrefSearch in Google Scholar
• 73 Chowdhury T, Gousy N, Bellamkonda A. et al. Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy. Cureus 2022; 14: e27773
  CrossrefPubMedSearch in Google Scholar
• 74 Ellegard L, Prytz M. Fournier’s gangrene under SGLT-2 inhibitor therapy: A literature review and case report. Int J Surg Case Rep 2020; 77: 692-694
  CrossrefPubMedSearch in Google Scholar
• 75 Leslie SW, Rad J, Foreman J. Fournier Gangrene. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024
  Search in Google Scholar
• 76 Colacci M, Fralick J, Odutayo A. et al. Sodium-Glucose Cotransporter-2 Inhibitors and Risk of Diabetic Ketoacidosis Among Adults With Type 2 Diabetes: A Systematic Review and Meta-Analysis. Canadian journal of diabetes 2022; 46: 10-15 e12
  CrossrefPubMedSearch in Google Scholar
• 77 Arzneimittelkommission der deutschen Ärzteschaft. Atypische diabetische Ketoazidosen im Zusammenhang mit SGLT-2-Hemmern (Gliflozine). Deutsches Ärzteblatt 2018; 115.
• 78 Kietaibl AT, Huber J, Clodi M. et al. Position statement: surgery and diabetes mellitus (Update 2023). Wien Klin Wochenschr 2023; 135: 256-271
  CrossrefPubMedSearch in Google Scholar
• 79 Schütt K, Aberle J, Bauersachs J. et al. Positionspapier Herzinsuffizienz und Diabetes. Die Kardiologie 2022; 16: 358-371
  CrossrefSearch in Google Scholar
• 80 Nasa P, Chaudhary S, Shrivastava PK. et al. Euglycemic diabetic ketoacidosis: A missed diagnosis. World J Diabetes 2021; 12: 514-523
  CrossrefPubMedSearch in Google Scholar
• 81 Hassanein M, Bashier A, Randeree H. et al. Use of SGLT2 inhibitors during Ramadan: An expert panel statement. Diabetes research and clinical practice 2020; 169: 108465
  CrossrefPubMedSearch in Google Scholar
• 82 Zaccardi F, Ling S, Lawson C. et al. Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study. Diabetologia 2020; 63: 2129-2139
  CrossrefPubMedSearch in Google Scholar
• 83 Hougen I, Whitlock RH, Komenda P. et al. Safety of add-on sulfonylurea therapy in patients with type 2 diabetes using metformin: a population-based real-world study. BMJ Open Diabetes Res Care 2021; 9
  CrossrefPubMedSearch in Google Scholar
• 84 Volke V, Katus U, Johannson A. et al. Systematic review and meta-analysis of head-to-head trials comparing sulfonylureas and low hypoglycaemic risk antidiabetic drugs. BMC endocrine disorders 2022; 22: 251
  CrossrefPubMedSearch in Google Scholar
• 85 Gemeinsamer Bundesausschuss (G-BA). Nutzenbewertung von Arzneimitteln. Accessed September 27, 2024 at: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/
• 86 Hellman M. SGLT2-Inhibitoren: fachmedizinische Aspekte aus hausärztlicher Sicht. Accessed September 27, 2024 at: https://www.esanum.de/conferences/der-internistenkongress/feeds/today/posts/sglt2-inhibitoren-hausaerzte
• 87 GKV-Spitzenverband. Anlage zur Vereinbarung nach § 130b Abs. 1 Satz 1 SGB V zwischen dem GKV-Spitzenverband und der Boehringer Ingelheim Pharma GmbH & Co. KG zum Arzneimittel Jardiance (Wirkstoff: Empagliflozin) bezüglich der Anerkennung einer Praxisbesonderheit. Accessed September 27, 2024 at: https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/amnog_praxisbesonderheiten/14034pb20170301.pdf
• 88 GKV-Spitzenverband. Anlage zur Vereinbarung nach § 130b Abs. 1 Satz 1 SGB V zwischen dem GKV-Spitzenverband und der AstraZeneca GmbH zum Arzneimittel Forxiga® (Wirkstoff: Dapagliflozin) bezüglich der Anerkennung einer Praxisbesonderhei. Accessed September 27, 2024 at: https://www.gkv-spitzenverband.de/media/dokumente/krankenversicherung_1/arzneimittel/amnog_praxisbesonderheiten/13016pb20230113.pdf
• 89 Morieri ML, Longato E, Di Camillo B. et al. Management of type 2 diabetes with a treat-to-benefit approach improved long-term cardiovascular outcomes under routine care. Cardiovascular diabetology 2022; 21: 274
  CrossrefPubMedSearch in Google Scholar
• 90 Boonman-de Winter LJ, Rutten FH, Cramer MJ. et al. High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes. Diabetologia 2012; 55: 2154-2162
  CrossrefPubMedSearch in Google Scholar
• 91 Tangri N, Moriyama T, Schneider MP. et al. Prevalence of undiagnosed stage 3 chronic kidney disease in France, Germany, Italy, Japan and the USA: results from the multinational observational REVEAL-CKD study. BMJ open 2023; 13: e067386
  CrossrefPubMedSearch in Google Scholar
• 92 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international 2024; 105: S117-S314
  CrossrefPubMedSearch in Google Scholar
• 93 McDonagh TA, Metra M, Adamo M. et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal 2023; 44: 3627-3639
  CrossrefPubMedSearch in Google Scholar